Vaccines company Valneva sticks to goal of COVID vaccine approvals in Q1

PARIS, Jan 6 (Reuters) – Speciality vaccines company Valneva (VLS.PA) said it was keeping its previous timetable on clinical trials and regulatory submissions for its VLA2001 COVID-19 vaccine candidate, with regulatory approvals targeted in the first quarter of this year.

The logo of French-Austrian biotech firm Valneva is seen outside their headquarters in Vienna, Austria, December 16, 2021. REUTERS/Lisi Niesner

“We continue to believe that our inactivated vaccine candidate could be an important component of the fight against COVID-19, and Valneva remains fully committed to bringing VLA2001 to people who need it as soon as we can,” said Valneva chief executive Thomas Lingelbach.

Reporting by Sudip Kar-Gupta Editing by Shri Navaratnam

Our Standards: The Thomson Reuters Trust Principles.

Reuters source: